Interleukin-18 in Brazilian Rheumatoid Arthritis Patients: Can Leflunomide Reduce It?

Objectives. Rheumatoid arthritis affects about 1% of the world’s population. This is a chronic autoimmune disease. It is predominant in females with progressive joint damage. Immune cells are involved, especially Th1/Th17 lymphocytes and their inflammatory cytokines. These proteins have different fu...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmune diseases 2021, Vol.2021, p.1-6
Main Authors: Gualberto Cardoso, Pablo Ramon, Diniz Lopes Marques, Claudia, de Melo Vilar, Kamila, Dantas, Andrea Tavares, Branco Pinto Duarte, Angela Luzia, Pitta, Ivan da Rocha, Galdino da Rocha Pitta, Maira, Barreto de Melo Rêgo, Moacyr Jesus
Format: Article
Language:English
Subjects:
Age
Arthritis
Autoimmune diseases
Cell activation
Chronic diseases
Cytokines
Disease
Helper cells
Immune system
Interleukin 16
Interleukin 18
Interleukins
Laboratories
Leflunomide
Lymphocytes T
Macrophages
NF-κB protein
Patients
Proteins
Rheumatoid arthritis
Rheumatoid factor
Rheumatology
Serum levels
Transcription
Tumor necrosis factor
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. Rheumatoid arthritis affects about 1% of the world’s population. This is a chronic autoimmune disease. It is predominant in females with progressive joint damage. Immune cells are involved, especially Th1/Th17 lymphocytes and their inflammatory cytokines. These proteins have different functions in the immune system, such as IL-16 is a chemotactic factor; IL-18 can activate NFκB transcription producing inflammatory proteins; IL-31 can activate the JAK/STAT pathway which leads to the production of inflammatory factors in chronic diseases; IL-33 promotes IL-16 secretion which causes lymphocyte recruitment, and IL-32 and IL-34 appear to increase TNF secretion by macrophages activation in AR. The aim of this study was to evaluate serum levels of IL-16, IL-18, IL-31, IL-32, IL-33, and IL-34 and compare them with the severity and treatment of RA patients if there are any correlations. Methods. A total of 140 RA patients and 40 healthy donors were recruited from the Department of Rheumatology at Hospital das Clínicas from the Federal University of Pernambuco. 60 AR patients were naïve for any treatment. Serum cytokine levels were determined using an ELISA kit. Results. Serum IL-16 (p = 0.0491), IL-18 (p 
ISSN:2090-0422
2090-0430
2090-0430
DOI:10.1155/2021/6672987